Publications by authors named "Lothar Lindemann"

Claim this Profile
O
Orally Bioavailable Dopamine D1/D5 Receptor-Biased Agonists to Study the Role of β-Arrestin in Treatment-Related Dyskinesia in Parkinson's Disease.
Rosa María Rodríguez Sarmiento, Stefan Berchtold, Nenad Manevski, Lothar Lindemann, Fabian Dey

J Med Chem· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Characterization of a Novel α-Synuclein-PEST H4 Cell Line for Enhanced Drug Screening in α-Synucleinopathies.
Nancy Carullo, Viktor Haellman, Simon Gutbier, Sonja Schlicht, Thien Thuong Nguyen, Lothar Lindemann

Int J Mol Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: γ‑Secretase modulator resistance of an aggressive Alzheimer‑causing presenilin mutant can be overcome in the heterozygous patient state by a set of advanced compounds.
Johannes Trambauer, Rosa Maria Rodriguez Sarmiento, Holly J Garringer, Katja Salbaum, Liliana D Pedro, Lothar Lindemann

Alzheimers Res Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
γ-Secretase modulator resistance of an aggressive Alzheimer-causing presenilin mutant can be overcome in the heterozygous patient state by a set of advanced compounds.
Johannes Trambauer, Rosa Maria Rodriguez Sarmiento, Holly J Garringer, Katja Salbaum, Liliana D Pedro, Lothar Lindemann

Alzheimers Res Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symmetric signal transduction and negative allosteric modulation of heterodimeric mGlu1/5 receptors.
Ruth C Werthmann, Manuel Tzouros, Jens Lamerz, Angélique Augustin, Thorsten Fritzius, Lothar Lindemann

Neuropharmacology· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex.
Elyza Kelly, Samantha M Schaeffer, Sameer C Dhamne, Jonathan O Lipton, Lothar Lindemann

Neuropsychopharmacology· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.
Elizabeth M Berry-Kravis, Lothar Lindemann, Aia E Jønch, George Apostol, Mark F Bear

Nat Rev Drug Discov· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results and evaluation of a first-in-human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods.
Stefan Sturm, Marie-Laure Delporte, Salah Hadi, Scott Schobel, Lothar Lindemann

Br J Clin Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
Eriene A Youssef, Elizabeth Berry-Kravis, Christian Czech, Randi J Hagerman, David Hessl, Lothar Lindemann

Neuropsychopharmacology· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences.
Daniel Peterlik, Christina Stangl, Amelie Bauer, Anna Bludau, Jana Keller, Lothar Lindemann

Brain Behav Immun· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabotropic glutamate receptor signaling is required for NMDA receptor-dependent ocular dominance plasticity and LTD in visual cortex.
Michael S Sidorov, Eitan S Kaplan, Emily K Osterweil, Lothar Lindemann, Mark F Bear

Proc Natl Acad Sci U S A· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.
Lothar Lindemann, Richard H Porter, Sebastian H Scharf, Basil Kuennecke, Andreas Bruns

J Pharmacol Exp Ther· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homer1/mGluR5 activity moderates vulnerability to chronic social stress.
Klaus V Wagner, Jakob Hartmann, Christiana Labermaier, Alexander S Häusl, Gengjing Zhao, Lothar Lindemann

Neuropsychopharmacology· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
Sebastian H Scharf, Georg Jaeschke, Joseph G Wettstein, Lothar Lindemann

Curr Opin Pharmacol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.
Georg Jaeschke, Sabine Kolczewski, Will Spooren, Eric Vieira, Nadia Bitter-Stoll, Lothar Lindemann

J Med Chem· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion.
Di Tian, Laura J Stoppel, Arnold J Heynen, Lothar Lindemann, Georg Jaeschke

Nat Neurosci· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of Bdnf gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer's disease.
Tomi Rantamäki, Susanna Kemppainen, Henri Autio, Saara Stavén, Hennariikka Koivisto, Lothar Lindemann

PLoS One· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.
Aubin Michalon, Andreas Bruns, Céline Risterucci, Michael Honer, Theresa M Ballard, Lothar Lindemann

Biol Psychiatry· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug discovery for autism spectrum disorder: challenges and opportunities.
Anirvan Ghosh, Aubin Michalon, Lothar Lindemann, Paulo Fontoura, Luca Santarelli

Nat Rev Drug Discov· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse.
Haruki Higashimori, Lydie Morel, James Huth, Lothar Lindemann, Chris Dulla

Hum Mol Genet· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders.
Will Spooren, Lothar Lindemann, Anirvan Ghosh, Luca Santarelli

Trends Pharmacol Sci· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of diazepam and MPEP on habituation and neuro-behavioural processes in inbred mice.
Amber R Salomons, Nathaly Espitia Pinzon, Hetty Boleij, Susanne Kirchhoff, Saskia S Arndt, Lothar Lindemann

Behav Brain Funct· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.
Aubin Michalon, Michael Sidorov, Theresa M Ballard, Laurence Ozmen, Will Spooren, Lothar Lindemann

Neuron· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice.
Jesse S O Lindholm, Henri Autio, Liisa Vesa, Hanna Antila, Lothar Lindemann

Neuropharmacology· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
Lothar Lindemann, Georg Jaeschke, Aubin Michalon, Eric Vieira, Michael Honer

J Pharmacol Exp Ther· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis